Madopar Hbs (Benserazide, Levodopa)

Madopar Hbs is indicated for the treatment of Parkinsonian disorders, where it helps restore dopaminergic activity in the central nervous system.

• Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity, tremor and gait disturbances, thereby enhancing daily activities.
• Parkinsonian syndrome: alleviates secondary parkinsonism features—including rigidity, tremor and postural instability—and supports functional mobility in affected patients.
• Levodopa‑responsive Parkinsonism: provides symptomatic relief by replenishing central dopamine, improving motor control when dopamine deficiency is the primary cause.
• Early‑stage Parkinson's disease: may delay the need for higher dose regimens and reduce motor fluctuations.

• Levodopa is absorbed from the gastrointestinal tract and crosses the blood‑brain barrier, where aromatic L‑amino acid decarboxylase converts it to dopamine, replenishing deficient central stores. Benserazide, administered concurrently, inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain, thereby increasing its central availability and reducing peripheral side effects.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset occurring shortly after dosing.
• Dizziness: often related to orthostatic changes, especially at treatment initiation.
• Headache: transient and usually resolves with dose adjustment.
• Insomnia: difficulty initiating or maintaining sleep.
• Orthostatic hypotension: drop in blood pressure upon standing, may cause light‑headedness.
• Dry mouth: reduced salivation leading to discomfort.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements that may become disabling.
• Psychiatric disturbances: hallucinations, confusion or mood swings, particularly in older patients.
• Severe hypotension: marked blood pressure fall requiring medical intervention.
• Cardiac arrhythmias: irregular heart rhythms observed in susceptible individuals.
• Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with fever, rigidity and autonomic instability.

Before initiating therapy, clinicians should consider the following precautions:

• Monitor blood pressure: watch for orthostatic hypotension, especially during dose titration.
• Assess for dyskinesia: adjust dose if involuntary movements become problematic.
• Avoid abrupt discontinuation: sudden withdrawal may worsen Parkinsonian symptoms.
• Use with caution in renal or hepatic impairment: altered metabolism may affect drug levels.
• Pregnancy and lactation: prescribe only if potential benefit outweighs potential risk to fetus or infant.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Madopar Hbs may interact with several medicines that affect dopaminergic pathways or cardiovascular function.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis due to excessive catecholamine levels.
• Antipsychotics (D2 antagonists): may block therapeutic effect of levodopa, reducing symptom control.
• Antihypertensive agents: additive hypotensive effect can lead to significant blood pressure drops.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may increase central side effects such as confusion or hallucinations.
• Iron or calcium supplements: can reduce levodopa absorption if taken concurrently.
• High‑protein meals: may compete for transport mechanisms, decreasing levodopa bioavailability.